article thumbnail

2025 Physician Wellness Retreats | Physician “Burnout” Retreats

Pamela Wible MD

Contact Dr. Wible to save your spot for the ultimate Oregon coast physician retreat—and become the author your patients are searching for. Join our private physician entrepreneur retreat where you’ll receive 1:1 guidance to build a coaching or consulting practice that reflects your passions and expertise. Ready to be your own boss?

article thumbnail

The FDA PDUFA VII Goals Letter (FY 2023-2027): A Review of Our Top 10 Commitments

FDA Law Blog

From new initiatives to facilitate faster reviews for new indications under the Split Real Time Application Review (STAR) pilot program, to bringing new meetings under PDUFA goals, to continued support for rare diseases and incorporation of the patient voice, the goals letter revealed a good number of welcome announcements.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Endocrinology, Diabetes and Metabolism Board Meeting Summary | Spring 2025

ABIM

Expanding ABIM’s engagement with stakeholder communities such as early career physicians, specialty societies and patient-focused organizations. They also noted a distinction in telehealth practices between remote consultations in different states and using telehealth to treat patients who live nearby.

article thumbnail

“TAP Dancing” Towards Faster Device Commercialization: CDRH’s Total Product Life Cycle Advisory (“TAP”) Program

FDA Law Blog

The striking phrase “valley of death,” is generally understood to refer to the tendency for innovative technologies to fail to reach market, whether due to reimbursement and/or physician or patient preference. up to 225 total products enrolled through FY 2026 and up to 325 total products enrolled through FY 2027).

article thumbnail

Less than Meets the Eye: LDT Small Entity Compliance Guide Adds Little Insight

FDA Law Blog

The guidance restates the central premise of the final rule, i.e., that LDTs are medical devices and the clinical laboratories that design, manufacture and use them to test patient specimens are manufacturers. establish and maintain adverse event files.” [9]

article thumbnail

Decades of LDT Tension Leads to an Epic Three-Hour Oral Argument

FDA Law Blog

Interestingly, counsel focused his arguments exclusively on parrying legal attacks, rather than arguing why the rule was necessary to protect patients. FDA had been scheduled to hold a webinar on the Stage 2 (May 2026) requirements related to the investigational device requirements for LDTs later this month.

article thumbnail

California’s Much-Touted IVF Law May Be Delayed Until 2026, Leaving Many in the Lurch

Physician's Weekly

Gavin Newsom has asked lawmakers to push the implementation date to January 2026, leaving patients, insurers, and employers in limbo. During IVF, a patient’s eggs are retrieved, combined with sperm in a lab, and then transferred to a person’s uterus. A single cycle can total around $25,000 , out of reach for many.